Response of reticulocyte and red blood cell indices to single-dose intravenous iron in pregnant women with moderate iron deficiency anemia: secondary analysis of the RAPIDIRON trial.
J Matern Fetal Neonatal MedApr 27, 2026 (epub)
Manjunath S Somannavar, Sudhir Mehta, Dharmesh Kumar Sharma et al.
✦ AI-curated · Sources linked
In 30 seconds
This secondary analysis of the RAPIDIRON trial evaluated the effects of single-dose intravenous iron on reticulocyte indices in pregnant women with moderate iron deficiency anemia. The study found that intravenous iron significantly improved red blood cell indices, with MCV increasing by 2.87 fL for ferric derisomaltose and 3.02 fL for ferric carboxymaltose compared to oral iron by mid-gestation.
Key findings
- MCV increased by 2.87 fL in the IV FDM group and 3.02 fL in the IV FCM group compared to oral iron.
- Ret-He levels significantly increased in IV FDM and FCM groups compared to oral iron.
- By 42 days postpartum, differences in Ret-He, IRF, and other parameters were no longer statistically significant.
Why it matters
Understanding the differential effects of intravenous versus oral iron therapy can help clinicians optimize treatment strategies for pregnant women with iron deficiency anemia, potentially improving maternal and fetal outcomes.